How to cite item

Adding chemotherapy to TKI: can we improve first-line treatment for EGFR-mutated NSCLC patients?

   
@article{TCR11308,
	author = {Francesco Passiglia and Antonio Russo},
	title = {Adding chemotherapy to TKI: can we improve first-line treatment for EGFR-mutated NSCLC patients?},
	journal = {Translational Cancer Research},
	volume = {5},
	number = {Suppl 7},
	year = {2016},
	keywords = {},
	abstract = {In The Journal of Clinical Oncology, Ying Cheng and colleagues (1) have recently reported the results of a phase II randomized trial comparing pemetrexed plus gefitinib vs. gefitinib in treatment-naive, East Asian patients, with advanced non-squamous non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations. The study met its primary end-point in the intent-to-treat population, showing a significantly longer median progression free survival (PFS) in favors of the combination arm (15.8 months) compared to single agent arm (10.9 months) [hazard ratio (HR): 0.68; 95% CI, 0.48 to 0.96; one-sided P=0.014; two-sided P=0.029].},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/11308}
}